Teosyal PureSense Ultra Deep 2x1.2ml
Important Notice
Regulated medical device (EU MDR 2017/745). For sale exclusively to qualified healthcare professionals.
What this purchase includes
- Original productFrom the manufacturer or an official distributor, CE marked.
- Batch and expiry documentedRecorded per unit on the delivery note and the invoice.
- Controlled storageOur own Madrid warehouse, 12 to 18 °C under 24 h control.
- Dispatch in 24 to 48 hFrom Madrid, insured and with a tracking number.
- Reachable Monday to Friday9:00 to 17:00 by WhatsApp and email. People, not forms.
Teosyal® PureSense Ultra Deep is the densest volumiser of the PureSense range: 25 mg/ml of hyaluronic acid with cross-linking below 10 %, in 1.2 ml syringes and with 25G 1" needles, the widest gauge and the greatest length in the whole Teosyal range. It is intended for the subcutaneous and supraperiosteal plane for volume restoration and contour remodelling.
- HA 25 mg/ml
- Cross-linking < 10 % (NMR)
- Lidocaine 0.3 % (3 mg/ml)
- Contents 2 syringes × 1.2 ml
- Needles 4 × 25G 1"
- Duration 15–18 months
Composition and technology
- Cross-linked hyaluronic acid: 25 mg/ml.
- Degree of cross-linking: < 10 %, measured by nuclear magnetic resonance.
- Lidocaine hydrochloride: 0.3 % by mass (3 mg/ml).
- Residual BDDE: < 1 ppm.
- Phosphate buffer pH 7.3 q.s. for 1.2 ml.
- Performance declared by the manufacturer: it creates a volume that corrects wrinkles or facial contours and restores skin hydration.
- Reading the gauge: the 25G 1" needle supplied indicates a high-density gel intended for deep planes; the superficial references of the range are supplied with 30G ½".
Position within the Teosyal PureSense range
| Redensity 1 | Non-cross-linked HA 15 mg/ml + dermo-restructuring complex · 1 ml · 30G ½" — skin quality and hydration · ≥ 3 months |
|---|---|
| Redensity 2 | HA 15 mg/ml (cross-linking < 10 %) + dermo-restructuring complex · 1 ml · 30G ½" — periorbital region and tear trough · ≥ 12 months |
| Global Action | HA 25 mg/ml · 1 ml — wrinkles and skin depressions, lips · 12–18 months |
| Deep Lines | HA 25 mg/ml · 1 ml — marked wrinkles and depressions · 12–18 months |
| Kiss | HA 25 mg/ml (cross-linking < 10 %) · 1 ml · 27G ½" — lips and perioral region · 12–18 months |
| Ultra Deep (this product) | HA 25 mg/ml (cross-linking < 10 %) · 1.2 ml · 25G 1" — facial volume and contour · 15–18 months |
| Ultimate | HA 22 mg/ml · 1 ml — facial contour · 15–18 months |
The cross-linked PureSense range declares a degree of cross-linking below 10 % (NMR), compared with the < 5 % of the RHA range. It is a firmer gel with a greater capacity for projection at an equal concentration; the RHA range instead prioritises adaptation to movement in areas of high facial animation. Redensity 1 falls outside this logic: it is not cross-linked and provides no volume.
Indications and treatment areas
Therapeutic indication: reconstructive surgery, filling of scar depressions and reconstruction of volumes lost through lipoatrophy in patients under treatment for HIV.
Aesthetic indication: correction of deep wrinkles and folds in areas of thick skin, remodelling of the facial contour, restoration and augmentation of volume and correction of mild tissue ptosis.
Technique and treatment protocol
- Injection plane: subcutaneous or supraperiosteal.
- Needles included: 25G 1", two per syringe (4 per pack).
- Cannula: a valid alternative is a 25G blunt cannula; compatibility verified by the manufacturer with TSK 25G/50 mm.
- Maximum volume: 6 ml per session.
- Estimated duration: between 15 and 18 months.
- Do not inject into the epidermis. Do not combine in the same session with peeling, laser or ultrasound.
Technical data
| Manufacturer | Teoxane SA (Laboratoires Teoxane), Geneva, Switzerland |
|---|---|
| Active substance | Cross-linked hyaluronic acid 25 mg/ml |
| Degree of cross-linking | < 10 % (NMR) |
| Anaesthetic | Lidocaine HCl 0.3 % by mass |
| Cross-linker | BDDE, residual < 1 ppm |
| pH | 7.3 (phosphate buffer) |
| Presentation | 2 pre-filled syringes of 1.2 ml |
| Needles | 4 × 25G 1" (2 per syringe) |
| Compatible cannula | 25G (TSK 25G/50 mm verified) |
| Treatment plane | Subcutaneous or supraperiosteal |
| Estimated duration | 15–18 months |
| Classification | CE-marked medical device |
| Use | Qualified healthcare professionals only |
Storage and pack contents
- Storage: between 2 °C and 25 °C, protected from direct sunlight.
- Do not use after the expiry date stated on the pack.
- Sterile single-use product. Do not reuse or re-sterilise the syringe or the needles.
- The pack contains: 2 pre-filled syringes of 1.2 ml, 4 sterile 25G 1" needles, and two traceability labels per syringe — one to be given to the patient and one for the medical record.
Contraindications and warnings
Contraindications: skin disorders, inflammation or infection in or near the treatment area; allergy to hyaluronic acid and a history of severe allergy or anaphylactic shock; allergy to lidocaine or to amide-type local anaesthetics; recent peel, laser or ultrasound treatment; autoimmune diseases; heart disease or treatment with beta-blockers; hepatocellular insufficiency or treatment for liver disease; epilepsy; porphyria; pregnancy, breastfeeding and patients under 18 years of age.
Vascular warning: intravascular injection may cause vascular occlusion, ischaemia and necrosis of the treated area. In the most serious cases it may lead to visual disturbances or blindness and to cerebral ischaemia or haemorrhage. Never inject intravascularly.
Before injection: do not treat if a dental procedure has been performed in the previous 15 days; avoid aspirin, anti-inflammatory drugs, anticoagulants and vitamin E during the preceding week; avoid alcohol and intense sun exposure on the previous day and on the day itself; remove make-up completely.
After injection: during the first 12 hours, do not apply make-up or undertake intense exertion; during the following week, avoid alcohol, prolonged sun or UV exposure, temperatures below 0 °C, sauna and hammam; for 15 days, do not undergo dental procedures or other aesthetic treatments.
Always consult the instructions for use included in the pack before treatment.
Medical device intended exclusively for qualified healthcare professionals. Technical information based on the official documentation of Teoxane SA (instructions for use TEOSYAL® PureSense ULTRA DEEP, ref. 230592-00, and patient product information). This information sheet does not replace the instructions for use supplied with the product.